Selank

Selank (CAS 129954-34-3, sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide derived from the endogenous immunopeptide tuftsin. In preclinical research, Selank has been studied for: anxiolytic effects in elevated plus maze and light-dark box models without sedation or motor impairment; modulation of GABA-A receptor sensitivity via a benzodiazepine-like mechanism without BZD binding; elevation of BDNF and NGF expression in hippocampal tissue; improvement in memory consolidation and learning in rodent models; modulation of serotonin and dopamine turnover in limbic regions; and immunomodulatory effects via tuftsin receptor activity. For research use only.

Selank and Semax are both synthetic neuropeptides developed by the same Russian research institution but with distinct primary profiles. Semax (derived from ACTH(4-10)) is studied for its effects on focus and cognitive processing in preclinical models, and for BDNF upregulation through a different pathway. Selank (derived from tuftsin) is primarily studied in anxiety models — investigated for anxiolytic-pathway modulation, memory consolidation under stress conditions, and limbic signalling without sedation in preclinical models. Semax is studied for cognitive activation; Selank for anxiolytic pathways. Both are available from Peptide Warehouse Australia for separate or combined research protocols. Not for human consumption — for research use only.

A key distinguishing feature of Selank in the research literature is its anxiolytic-without-sedation profile. In rodent studies using rotarod tests and open field locomotion assessments, Selank does not produce the motor coordination deficits or sedation observed with benzodiazepines. The proposed mechanism — modulation of GABA-A receptor sensitivity rather than direct receptor agonism — may explain this distinction. Preclinical dependence models have not demonstrated the tolerance or withdrawal profiles associated with classical BZD anxiolytics. These are research findings in animal models. Not for human consumption — for research use only.

Reconstitution: Draw 1–2mL of bacteriostatic water into a clean 31G insulin syringe. Inject slowly down the inside wall of the Selank vial. Gently swirl until fully dissolved. The solution should be clear and colourless. Common concentration: 1mL BAC water = 10mg/mL. Storage: Lyophilised — store at −20°C for up to 24 months. Reconstituted — refrigerate at 2–8°C and use within 28 days. Protect from light.

Selank is legal to purchase in Australia for legitimate laboratory research purposes. It is not listed as a scheduled substance under the Poisons Standard when sold for research use only. Purchasers must be 18+ and confirm research-only use. It is not TGA-approved for human consumption, therapeutic, or veterinary use. Our Selank 10mg is manufactured to a >99% HPLC purity specification. Peptide Warehouse Australia dispatches nationwide from our Melbourne warehouse via Australia Post.

Peptide Warehouse Australia stocks research-grade Selank 10mg and dispatches nationwide via Australia Post with full tracking from our Melbourne warehouse. Orders placed before 12PM AEST dispatch the same business day; orders after 12PM AEST dispatch the next business day. Standard Post (2–6 business days) $8.99; Express Post (1–3 business days) $13.99. Free shipping on orders over $199 AUD. Discreet plain packaging, no external branding.

Selank is a synthetic analogue of the immunomodulatory peptide tuftsin, studied for anxiolytic and immunomodulatory effects in preclinical models. Its tuftsin-derived structure underlies research into pathways distinct from classical neurotransmitter-targeting compounds. Not for human consumption — for research use only.

Selank has been studied for effects on GABAergic and serotonergic signalling, as well as on the expression of brain-derived neurotrophic factor (BDNF), in preclinical anxiolytic and cognitive research models. These pathways are the basis for its research interest. Not for human consumption — for research use only.

Unlike benzodiazepines, which act directly as GABA-A receptor positive modulators, Selank is studied as a peptide that influences GABAergic and serotonergic tone indirectly, and research interest includes its lack of the sedation and dependence profile associated with benzodiazepines. They are mechanistically distinct research subjects. Not for human consumption — for research use only.

Selank has been studied in research using intranasal and parenteral routes, with the route determined by the experimental protocol. Our Selank is supplied as a lyophilised research-grade powder; reconstitution and route are chosen by the researcher according to their model. Not for human consumption — for research use only.

Selank is a research nootropic peptide based on a tuftsin fragment, also written TP-7. It is studied alongside its relative Semax. For in-vitro research use only.